Aratana Therapeutics Inc (PETX) Releases Earnings Results, Beats Expectations By $1.03 EPS

Aratana Therapeutics Inc (PETX) reported quarterly earnings results on Thursday, Aug-4-2016. The company said it had a profit of $0.61 Earnings per Share for the quarter. The results exceeded Wall Street expectations beating the analyst consensus estimate by $1.03. Analysts had a consensus of $-0.42. Analysts expectations of $.12 million. During the same quarter in the previous year, the company posted $-0.23 EPS.

Aratana Therapeutics Inc opened for trading at $7.44 and hit $7.735 on the upside on Tusday, eventually ending the session at $7.62, with a gain of 1.60% or 0.12 points. The heightened volatility saw the trading volume jump to 5,78,730 shares. Company has a market cap of $269 M.

In a different news, on Jun 28, 2016, Julia A Stephanus (CHIEF COMMERCIAL OFFICER) sold 30,000 shares at $6.25 per share price. According to the SEC, on Jun 17, 2016, Peter Steven St (PRESIDENT AND CEO) sold 100,000 shares at $6.28 per share price. On Jun 13, 2016, Ernst Heinen (Chief Development Officer) sold 15,000 shares at $6.72 per share price, according to the Form-4 filing with the securities and exchange commission.

Aratana Therapeutics Inc. is a pet therapeutics company focused on licensing developing and commercializing of biopharmaceutical products for companion animals. The Company has licensed and is developing more than 18 therapeutic candidates in development consisting of small molecule pharmaceuticals and large molecule biologics that target serious medical conditions such as pain and inflammation stimulation of appetite cancer and other serious diseases for dogs and cats. These product candidates are in various stages of development for the treatment of cats or dogs or both. The Company’s target indications include pain and inflammation associated with osteoarthritis inappetence post-operative pain lymphoma osteosarcoma atopic dermatitis ocular herpes and feline immunodeficiency virus. The Company’s most advanced products from a development and commercialization perspective AT-004 and AT-005 are monoclonal antibodies (MAbs) for treating lymphoma in dogs.

Aratana Therapeutics Inc

Leave a Reply

Aratana Therapeutics Inc - Is it time to Sell?

Top Brokerage Firms are advising their investors on Aratana Therapeutics Inc. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.